ArticleCancer immunology, immunotherapy : CII2024

ALK5/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects.

Nam-Hoon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.